Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: YAZ and YAZ + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and YAZ + Levomefolate Calcium (Metafolin)
Information source: Bayer
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Contraception
Intervention: EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300) (Drug); EE 0.02 mg/DRSP 3 mg/L-5-MTHF Ca 0.451 mg (EE20/DRSP/L-5-MTHF Ca) (Drug); L-5-MTHF 0.451mg (Metafolin) (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Bayer Official(s) and/or principal investigator(s): Bayer Study Director, Study Director, Affiliation: Bayer
Summary
The purpose of this study is examine and compare the uptake of YAZ (oral contraceptive
containing drospirenone and ethinylestradiol) with or without levomefolate calcium
(Metafolin, a registered vitamin supplement) in the body and to examine and compare the
uptake of levomefolate calcium with or without YAZ in the body, in healthy volunteers not
using hormonal contraception
Clinical Details
Official title: Open-label, Randomized, Three-fold Crossover Study to Investigate the Bioequivalence of Two Different Tablet Formulations Containing 0.02 mg Ethinylestradiol (EE) and 3 mg Drospirenone (DRSP) Without [SH T00186D] and With [SH T04532B] 0.451 mg L-mefolinate (Metafolin), and to Investigate the Bioequivalence of Two Different Tablet Formulations Containing 0.451 mg L-mefolinate (Metafolin) Without [SH T04532C] and With 0.02 mg EE/ 3 mg DRSP [SH T04532B] in 42 Healthy Young Women
Study design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Mean Maximum Concentration (Cmax) of EE Incl. Bioequivalence (BE) EvaluationMean Area Under the Concentration-time Curve From Administration to the Last Measurement [AUC(0-tlast)] of EE Incl. Bioequivalence (BE) Evaluation Mean Maximum Concentration (Cmax) of DRSP Incl. Bioequivalence (BE) Evaluation Mean Area Under the Concentration-time Curve From Administration to the Last Measurement [AUC(0-tlast)] of DRSP Incl. Bioequivalence (BE) Evaluation Mean Maximum Concentration (Cmax) of L-5-methyl-THF (Baseline Corrected) Incl. Bioequivalence (BE) Evaluation Mean Area Under the Concentration-time Curve From Administration to the Last Measurement [AUC(0-tlast)] of L-5-methyl-THF (Baseline Corrected) Incl. Bioequivalence (BE) Evaluation Mean Maximum Concentration (Cmax) of L-5-methyl-THF (Baseline Uncorrected) Incl. Bioequivalence (BE) Evaluation Mean Area Under the Concentration-time Curve From Administration to the Last Measurement [AUC(0-tlast)] of L-5-methyl-THF (Baseline Uncorrected) Incl. Bioequivalence (BE) Evaluation
Secondary outcome: Time to Reach Maximum Concentration (Tmax) of EEMean Area Under the Concentration-time Curve From Administration up to 72h AUC(0-72h) of DRSP Time to Reach Maximum Concentration (Tmax) of DRSP Time to Reach Maximum Concentration (Tmax) of L-5-methyl-THF
Eligibility
Minimum age: 18 Years.
Maximum age: 38 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- Healthy female volunteer
- Age: 18 - 38 years inclusive
- Body mass index (BMI)1: ≥ 19 and < 28 kg/m²
- Regular cyclic menstrual periods at screening OR when using combined oral
contraceptives during the recruitment period reporting of natural cyclic menstrual
periods prior to their use
- Willingness to use non-hormonal methods of contraception during the complete trial OR
previous tubal ligation
Exclusion Criteria:
- incompletely cured pre-existing diseases for which it can be assumed that the
absorption, distribution, metabolism, excretion and effect of the study drugs will
not be normal
- known or suspected sex-steroid influenced malignancies
- endometrial hyperplasia; genital bleeding of unknown origin; uterus myomatosus
- known or suspected tumors of the liver and pituitary
- presence or history of severe hepatic disease as long as liver function values have
not returned to normal
- severe renal insufficiency or acute renal failure
- thrombophlebitis, venous / arterial thromboembolic diseases; presence or history of
prodromi of a thrombosis
- other conditions that increase susceptibility to thromboembolic diseases
- known neuropsychiatric diseases, especially known or suspected epilepsy, and/ or
deficient status of folate or vitamin B12
- use of any other medication within 2 cycles before first study drug administration
which could affect the study aim
- use of potassium sparing drugs; use of folic acid containing supplements or medicines
or use of any medication within 2 cycles before first study drug administration known
to interfere with folate metabolism
- inadequate folate and/or Vitamin B12 status, clinically relevant deviations in red
cell folate concentrations
Locations and Contacts
Dinox B.V., Groningen 9713GZ, Netherlands
Additional Information
Click here and search for drug information provided by the FDA. Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.
Starting date: October 2006
Last updated: August 1, 2013
|